The Effect of Soluble Epoxide Hydrolase (SEH) on Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

330 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-01

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depression is the most common mental disease and the second leading cause of chronic disease burden, which is closely related to suicidal behavior. The diagnosis and treatment of depression still lack of effective biological indicators, and about 30% of patients with depression still can not relieve their depressive symptoms after treatment. Previous studies have found that ATP release from astrocytes plays an important role in the occurrence, development and treatment of depression. Epoxy eicosotrienes (eets) are closely related to the function of the nervous system and may be the pathophysiological mechanism of depression. Soluble epoxide hydrolase (SEH) can regulate ATP release by affecting EET degradation, leading to depression like behavior and antidepressant effect, and sEH is closely related to cognitive function of depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study

NCT07203144

Depression - Major Depressive Disorder

NOT_YET_RECRUITING PHASE2

Prospective Clinical Cohort Study of Depression

NCT05775809

Major Depressive Disorder

UNKNOWN

Exploring the Experience of Communication for Patients With Depression

NCT01727674

Depression

UNKNOWN

Establish a Specific Cohort Database for Depressive Disorders

NCT05095662

Depressive Disorder

ACTIVE_NOT_RECRUITING

Characterization of Suicidal Depression

NCT05046587

Depression

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an observational study without any intervention treatment for the subjects. All subjects need to sign the informed consent before screening, and the successful subjects can enter the study. Routine clinical diagnosis and treatment were performed on patients with depression, and the treatment effect of depressive symptoms, neurocognitive function and suicide improvement were evaluated at the 2nd week, 1st, 2nd, 3rd, 6th and 12th months after enrollment, and statistical analysis was conducted. The treatment lasted until the subjects completed the 12th month follow-up or reached any of the withdrawal criteria. This study will clarify the relationship between sEH gene polymorphism and mRNA expression and depression and suicide behavior, and explore the predictive role of soluble epoxide hydrolase sEH in the treatment effect of depression, cognition and suicide improvement during the follow-up study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Major depressive disorder

Patients diagnosed with severe depressive episode according to the diagnostic and Statistical Manual of mental disorders, 5th Edition (DSM-V);

No interventions assigned to this group

healthy volunteer

Person who did not meet the DSM-V diagnosis of any mental disease, had no family history of psychiatric disease, and had no history of suicidal behavior.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntarily sign informed consent;
2. Age: 18-65 years old;
3. Elementary school or above, able to understand and complete all inspections and assessments;
4. Did not take any psychotropic drugs (including benzodiazepines) within 2 weeks before enrollment;
5. After routine medical diagnosis by clinicians, they were divided into depression and healthy people.

Exclusion Criteria

1. Severe somatic or neurological diseases;
2. Mental retardation and dementia;
3. During pregnancy or breastfeeding;
4. Heavy smoking, alcoholism and other substance abuse or dependence (within 3 months before enrollment);
5. Electric shock treatment (within 3 months before enrollment);
6. According to the judgment of the investigator, it is not suitable to participate in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes